Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial

benzinga.com/news/health-care/25/07/46500849/bristol-myers-drug-flunks-blood-cancer-associated-anemia-trial

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell…

This story appeared on benzinga.com, 2025-07-18 17:54:13.
The Entire Business World on a Single Page. Free to Use →